The study, presented at the 15th International Headache Congress in Berlin, tested St. Jude Medical’s Genesis neurostimulator.
At one year, 66 percent of patients reported excellent or good pain relief. Patients logged a 41 percent improvement on the Migraine Disability Assessment questionnaire, compared with a 13 percent improvement in a placebo group.
Read the St. Jude Medical release on peripheral nerve stimulation.
Related Articles on Neurostimulation:
Medtronic, St. Jude Developing Competing Neurostimulation Systems
SPR Therapeutics Nabs $250K Investment for Pain Relief Device
Study: Nerve Blockade Reduces Acute Pain After Hip Fracture
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.